Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:104741
Structure:
Synonyms:
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
129453-61-8
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
C32H47F5O3S
D01161
DB00947
Estra-1,3,5(10)-triene-3,17-diol,
Estra-1,3,5(10)-triene-3,17-diol, 7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-, (7alpha,17beta)-
Faslodex
Faslodex (TN)
Faslodex(ICI 182,780)
Faslodex, ICI 182780, Fulvestrant
Fulvestrant
Fulvestrant (JAN/USAN/INN)
Fulvestrant [USAN]
ICI 182,780
ICI 182,789
Ici 182780
ICI-182780
LS-64781
nchembio.168-comp5
nchembio.76-comp5
nchembio775-comp4
NSC719276
ZD 182780
ZD-182780
ZD-9238
ZM 182780
ZM-182780
ATC-Codes:
Side-Effects:
Side-EffectFrequency
abdominal pain0.0010
flu syndrome0.0010
nausea0.0010
pain0.0010
paresthesia0.0010
pelvic pain0.0010
pharyngitis0.0010
pruritus0.0010
sweating0.0010
urinary tract infections0.0010
urticaria0.0010
vomiting0.0010
peripheral edema0.0010
bone pain0.0010
elevated liver enzymes0.0010
breast cancer0.0010
insomnia0.0010
hypersensitivity0.0010
headache0.0010
anemia0.0010
angioedema and urticaria0.0010
anorexia0.0010
anxiety0.0010
arthritis0.0010
asthenia0.0010
back pain0.0010
chest pain0.0010
constipation0.0010
flushes0.0010
fever0.0010
skin rash0.0010
dyspnea0.0010
dizziness0.0010
diarrhea0.0010
cough0.0010
hemorrhage0
vaginal hemorrhage0
vertigo0
myalgia0
leukopenia0

Target

show target details
Uniprot ID:Q9UBT1_HUMAN
Synonyms:
Estrogen receptor
EC-Numbers:-
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----
----
----

References:

016046614
12626428
17beta-estradiol activates ICI 182,780-sensitive estrogen receptors and cyclic GMP-dependent thioredoxin expression for neuroprotection.. Sang Y Lee; Tsugunobu Andoh; Dennis L Murphy; Chuang C Chiueh (2003) The FASEB journal : official publication of the Federation of American Societies for Experimental Biology display abstract
Clinical studies suggest that estrogen may improve cognition in Alzheimer's patients. Basic experiments demonstrate that 17beta-estradiol protects against neurodegeneration in both cell and animal models. In the present study, a human SH-SY5Y cell model was used to investigate molecular mechanisms underlying the receptor-mediated neuroprotection of physiological concentrations of 17beta-estradiol. 17beta-estradiol (
16473018
Fulvestrant ('Faslodex'): current and future role in breast cancer management.. Anthony Howell (2006) Critical reviews in oncology/hematology display abstract
Fulvestrant ('Faslodex') is a new type of estrogen receptor antagonist with no agonist effects, that reduces cellular levels of both estrogen and progesterone receptors. Results from two Phase III trials showed that fulvestrant is at least as effective as the third-generation selective aromatase inhibitor anastrozole in postmenopausal women with advanced breast cancer following progression on antiestrogen therapy, indicating the potential for second-line fulvestrant in this setting. In clinical practice, fulvestrant is well tolerated, with good rates of clinical benefit observed as first-line therapy and following progression on prior endocrine agents. Other endocrine agents have been shown to have good clinical activity when resistance to fulvestrant has developed, showing that fulvestrant lacks cross-resistance with other treatments. Ongoing trials are investigating the efficacy of fulvestrant after failure on aromatase inhibitors and evaluating its use in combination with therapies that target growth factor receptor signaling pathways.